Weekly Top News – Ovarian Cancer – September 7, 2020

llllllllll Lynparza (olaparib) / Merck (MSD), AstraZeneca; Keytruda (pembrolizumab) / Merck (MSD); Lenvima (lenvatinib) / Eisai, Merck (MSD)New Scientific Data at the ESMO Virtual Congress 2020 Reflect Merck’s Commitment to Advancing Cancer Research and Care (Businesswire) - Sep 2, 2020 - "Data spanning more than 15 types of cancer will be presented at the congress, with new findings from Merck’s portfolio of established medicines including KEYTRUDA, Merck’s anti-PD-1 therapy; LENVIMA® (lenvatinib, in collaboration with Eisai); and LYNPARZA (in collaboration with AstraZeneca). Pivotal Phase 3 data evaluating KEYTRUDA in combination with chemotherapy for the first-line treatment of patients with locally advanced or metastatic esophageal cancer from the KEYNOTE-590 trial (Abstract #LBA8) and LYNPARZA in patients with metastatic castration-resistant prostate cancer (mCRPC) from the PROfound trial (Abstract #610O) were selected for inclusion in ESMO Presidential Symposium sessions. Additionally, new findings will be shared for three of Merck’s novel investigational candidates: vibostolimab (MK-7684), an anti-TIGIT antibody; MK-4830, an antibody targeting ILT4; and MK-6482, an oral HIF-2α inhibitor."llllllllll Lynparza (olaparib) / Merck (MSD), AstraZenecaOVAL-1: Olaparib Real-world Utilization and Clinical Outcomes in France, Italy, and the UK (clinicaltrials.gov) - Aug 31, 2020 - P; N=350; Not yet recruiting; Sponsor: AstraZenecallllllllll SL-172154 / ShattuckShattuck Labs Announces Initiation of Phase 1 Clinical Trial of SL-172154 (SIRPα-Fc-CD40L) for the Treatment of Ovarian Cancer (Businesswire) - Aug 31, 2020 - "Shattuck Labs, Inc…announced initiation of a Phase 1 clinical trial of its compound SL-172154 (SIRPα-Fc-CD40L), a bi-functional fusion protein that simultaneously blocks the CD47/SIRPα checkpoint and activates the tumor necrosis factor (TNF) costimulatory receptor CD40….Initial clinical data from the trial are expected in the second half of 2021. In addition, Shattuck plans to evaluate SL-172154 in combination with other therapeutic agents in specific cancers."